Company Active LTD

Company profile

Cambridge Innovation Technologies Consulting Limited

ERROR: The requested URL could not be retrieved

Cambridge Innovation Technologies Consulting Limited is a UK company with status active founded in 2014 based in East of England.

CRN
09144414
Founded
2014
Age
11

Overview

Legal name
CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED
Region
East of England
Registered address
ST JOHN'S INNOVATION CENTRE
COWLEY ROAD
CAMBRIDGE
ENGLAND
CB4 0WS
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Cambridge Innovation Technologies Consulting Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Aug 2023 to 31 Jul 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
3

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Jul
2026

Accounts due

Accounts Due

Next accounts due date

14 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jul
2024

Accounts filed

Accounts

Last accounts made up date

23 Jul
2014

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2017
Funded years
2017, 2019, 2020, 2023
Age at first award
2 years

Projects

2023 EU-Funded Lead participant

Development of a multifunctional biomaterial patch for buccal delivery of peptide-analogue treatments

1 Jan 2023 to 31 Dec 2026

Awarded
£344,717
Total cost £344,717

no public description

2020 Feasibility Studies Lead participant

humaNase Continuity

1 Jun 2020 to 31 Mar 2021

Awarded
£37,093
Total cost £37,093

no public description

2019 Feasibility Studies Lead participant

humaNase

1 May 2019 to 31 Mar 2021

Awarded
£69,685
Total cost £99,550

"Cancer cells undergo complex metabolic changes and require the amino acid L-asparagine (ASN) to grow. Starving cancers by depriving them of ASN is a powerful anticancer strategy, notably in the treatment of Acute Lymphoblastic Leukaemia (ALL). ALL is the most common cancer in children, however adults with the disease have a particularly poor survival out...

2017 Feasibility Studies

Resilient Electronic Patch enabled by printed energy storage devices (RE-Patch)

1 Jun 2017 to 31 May 2018

Awarded
£43,337
Total cost £61,910

Picture a band-aid. Visualise how thin, flexible and light it is. How it adapts its shape to your body and how reassuring and seamless it feels to have it on. Now imagine that band-aid is a personal well-being monitor with sensors measuring health and environmental parameters and the capacity to communicate wirelessly with the wearer and the carer when a ...

Product types

EU-Funded Feasibility Studies